Harry Harry and and the second --17. (Amended) --19. (Amended)

B. Jack Longley Applicants: Not Yet Known Serial No.: December 29, 1999 Filed

Page 2

with an antibody, peptide, or nonpeptide chemical.--

The \method of [any one of claims 1-9] claim --15. (Amended) kit inhibiting comprises which 1, dimer\(\frac{1}{2}\)zation with an antibody, peptide, or nonpeptide chemical.--

The method of [any one of claims 1-9] claim --16. (Amended) $\underline{1}$, whereih downstream signaling of the kit activation\pathway is inhibited by blocking association with kit kinase substrate domain.--

> The method of $\left(\text{any one of claims 1-9} \right)$ 1, wherein downstream signaling of the kit activation pathway is inhibited by blocking the downstream in fundtion enzymatic signaling pathway .--

The method of $\{any \setminus one of claims 1-9\}$ claim 1, wherein downstream signaling of the kit activation pathway ia inhibited by blocking in the downstream binding of molecules signaling pathway.--

The method of [any one of claims 1-9] claim 1, wherein the compound is an antibody or portion thereof. --

The method of claim [22] 19, wherein the [anti-kit] antibody is ACK2.--

The method of [any one of claims 1-9] claim 1, wherein the compound comprises a Fab

--18. (Amended)

(Amended)

--24. (Amended)

Applicants: Serial No.: B. Jack Longley Not Yet Known

Filed

December 29, 1999

Page 3

Aragment of an anti-kit antibody. --

--25. (Amended)

The method of [any one of claims 1-9] claim wherein the compound comprises the variable domain of an anti-kit antibody.--

-26. (Amended)

The method of [any one of claims 1-9] claim 1, wherein the compound comprises one or more CDR portions of an anti-kit antibody .--

-28. (Amended)

The method of [any one of claims 1-9] claim 1, wherein the compound comprises a peptide, peptidomimetic, a nucleic acid, organic compound with a molecular weight less than 500 Daltons. --

-29. (Amended)

The method of [any one of claims 1-9] claim 1, wherein the compound is sSCF, sKIT ligand or a fragment thereof .--

--30. (Amended)

The method of [an one of claims 1-9] claim wherein the compound is sKIT or fragment thereof. --

--31. (Amended)

The method of [any one of claims 1-9] claim 1, wherein the subject is a mammal. --

(Amended)

The method of [any one of claims 1-9] claim administration 1, wherein the is intralesional, intraperitoneal, intramuscular, subcutaneous, intravenous, liposome mediated delivery transmucosal, oral, intestinal, topical, nasal, anal, ocular or otic delivery.

the Mary Land Thank West 19